Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial
M Shibata, A Nihira, Y Tanji, A Ozeki, H Imagawa… - Neurology and …, 2023 - Springer
Introduction The efficacy and safety of galcanezumab as a preventive treatment in Japanese
patients with episodic migraine was demonstrated in a phase 2, randomized, placebo …
patients with episodic migraine was demonstrated in a phase 2, randomized, placebo …
A digital health application allowing a personalized low-glycemic nutrition for the prophylaxis of migraine: proof-of-concept data from a retrospective cohort study
T Schröder, G Kühn, A Kordowski, SR Jahromi… - Journal of Clinical …, 2022 - mdpi.com
Background: Migraine is a headache disorder with the highest socioeconomic burden. The
aim of this study was to deliver the first proof-of-concept data of the potential role of an …
aim of this study was to deliver the first proof-of-concept data of the potential role of an …
Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four …
M Ashina, DD Mitsikostas… - … : The Journal of …, 2023 - Wiley Online Library
Objective This study aimed to determine the number needed to treat (NNT), number needed
to harm (NNH), and likelihood of being helped or harmed (LHH) in a post hoc analysis of the …
to harm (NNH), and likelihood of being helped or harmed (LHH) in a post hoc analysis of the …
Developments in targeting calcitonin gene-related peptide
S Alabbad, N Figueredo, H Yuan… - Expert Review of …, 2024 - Taylor & Francis
ABSTRACT Introduction Calcitonin Gene-Related Peptide (CGRP)-targeted therapy has
revolutionized migraine treatment since its first approval in 2018. CGRP-targeted therapy …
revolutionized migraine treatment since its first approval in 2018. CGRP-targeted therapy …
Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials
J Tobin, JH Ford, A Tockhorn-Heidenreich… - Journal of Medical …, 2022 - Taylor & Francis
Aim This post-hoc analysis estimated annual indirect cost savings with galcanezumab
(GMB) treatment in patients with episodic migraine (EM) or chronic migraine (CM). Methods …
(GMB) treatment in patients with episodic migraine (EM) or chronic migraine (CM). Methods …
Atogepant for the prevention of episodic migraine in adults
MP Switzer, JE Robinson, KR Joyner… - SAGE Open …, 2022 - journals.sagepub.com
Objective: Atogepant is a newly approved medication for the prevention of migraine. This
review aims to discuss the efficacy, safety, cost, and place in therapy of atogepant. Methods …
review aims to discuss the efficacy, safety, cost, and place in therapy of atogepant. Methods …
Effects of galcanezumab on health-related quality of life and disability in patients with previous failure of 2–4 migraine preventive medication categories: results from a …
Abstract Background and Objectives Patients with migraine and prior preventive treatment
failures have a significant burden on quality of life and disability. The CONQUER study …
failures have a significant burden on quality of life and disability. The CONQUER study …
The history and rationale of the development of new drugs for migraine treatment
PA Kowacs, PAS Rocha-Filho… - Arquivos de Neuro …, 2023 - thieme-connect.com
Migraine is one of the most prevalent and disabling diseases in the world. Migraine attack
treatments and prophylactic treatments of this disease are essential to lessen its individual …
treatments and prophylactic treatments of this disease are essential to lessen its individual …
Could erectile dysfunction be a side effect of CGRP inhibition? A case report
L Al-Hassany, T Vries, JA Carpay… - …, 2022 - journals.sagepub.com
Background Recently, antimigraine drugs targeting the calcitonin gene-related peptide
pathway have been approved for clinical use as preventive migraine medication. Case …
pathway have been approved for clinical use as preventive migraine medication. Case …
Benefit–risk assessment of galcanezumab versus placebo for the treatment of episodic and chronic migraine using the metrics of number needed to treat and number …
L Citrome, M Sánchez del Rio, Y Dong, RM Nichols… - Advances in …, 2021 - Springer
Introduction Subcutaneous galcanezumab was an effective, well-tolerated preventive
treatment for adults with episodic (EM) or chronic migraine (CM) in 4 phase 3 randomized …
treatment for adults with episodic (EM) or chronic migraine (CM) in 4 phase 3 randomized …